ABRs and hemostatic success of patients during the temporarily decreased IR period or during the duration of this analysis of pathfinder6
| . | During temporarily decreased IR: patients with temporarily decreased IR . | Total observation time . | |
|---|---|---|---|
| Patients with temporarily decreased IR . | Other non-inhibitor patients . | ||
| No. of patients | 17 | 17 | 42 |
| No. of patients with bleeds, n (%) | 14 (82.4) | 17 (100) | 37 (88.1) |
| Mean treatment period, y | 0.48 | 2.17 | 2.39 |
| Estimated ABR (95% CI)∗ | 4.14 (2.45; 7.00) | 2.41 (1.64; 3.52) | 2.75 (1.97; 3.84) |
| Median ABR (IQR) | 4.42 (1.17; 7.03) | 2.34 (1.23; 5.45) | 1.52 (0.80; 4.54) |
| . | During temporarily decreased IR: patients with temporarily decreased IR . | Total observation time . | |
|---|---|---|---|
| Patients with temporarily decreased IR . | Other non-inhibitor patients . | ||
| No. of patients | 17 | 17 | 42 |
| No. of patients with bleeds, n (%) | 14 (82.4) | 17 (100) | 37 (88.1) |
| Mean treatment period, y | 0.48 | 2.17 | 2.39 |
| Estimated ABR (95% CI)∗ | 4.14 (2.45; 7.00) | 2.41 (1.64; 3.52) | 2.75 (1.97; 3.84) |
| Median ABR (IQR) | 4.42 (1.17; 7.03) | 2.34 (1.23; 5.45) | 1.52 (0.80; 4.54) |
Temporarily decreased IR defined as patients with an observation of 2 consecutive measurements of IR <0.6 (IU/dL)/(IU/kg) without inhibitors. CI, confidence interval.
Based on a negative binomial model with the log of treatment duration as an offset.